MedTrace Logo

Argipressin's Influence on Blood Loss During Hepatic Resection

NCT05293041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2025-03-06

No results posted yet for this study

Summary

Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo. Subjects will be randomized to infusion of Argipressin or placebo during surgery. Blood loss, transfusion requirements, surgical data including length of stay in hsopital, inflammatory markers and markers of renal- intestinal- and cardiac injury will be assessed. Two sub-studies has been added; one for evaluation of coagulation function, and one for assessment of pain scores and morphine consumption.

Conditions

  • Colon Cancer Liver Metastasis
  • Inflammatory Response
  • Vasopressin Causing Adverse Effects in Therapeutic Use

Interventions

DRUG

Argipressin

Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.

DRUG

Placebo

Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.

Sponsors & Collaborators

  • Kristina Svennerholm

    lead OTHER

Principal Investigators

  • kristina svennerholm, MD PhD · Senior Consultant Anesthesia and Intensive Care, Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-27
Primary Completion
2024-12-06
Completion
2025-02-17

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05293041 on ClinicalTrials.gov